Showing results (71-80 of 85) with videos related to
Sort By:
Pageof 9
British Journal of Cancer|January 14, 2012
Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancerG R Simpson, A Horvath, N E Annels, et al.Journal of Medicinal Chemistry|February 26, 2000
Inhibitors of tripeptidyl peptidase II. 2. Generation of the first novel lead inhibitor of cholecystokinin-8-inactivating peptidase: a strategy for the design of peptidase inhibitorsC R Ganellin, P B Bishop, R B Bambal, et al.Diabetes|March 18, 2024
Genetic Evidence of Causal Relation Between Intestinal Glucose Absorption and Early Postprandial Glucose Response: A Mendelian Randomization StudySimon Peschard, Violeta Raverdy, Pierre Bauvin, et al.Scientific Reports|July 10, 2026
Intestinal FXR deficiency uncouples steatosis protection from liver inflammation and fibrosis in MASH-diet fed miceMargaux Nawrot, Simon Peschard, Morgane M Thibaut, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 19, 2026
Relationship Between Baseline and Longitudinal Self-Reported Physical Function and Cardiorenal Outcomes in CKD: Findings From the CRIC StudyVanessa-Giselle Peschard, Wei Yang, Xiaoming Zhang, et al.Psychiatry Research|September 27, 2022
Association between CLOCK gene polymorphisms and ADHD in Mexican teenagers: A comprehensive assessmentAlfonso Cabrera Lagunes, Adriana Díaz-Anzaldúa, Gustavo Rojas Andrade, et al.The British Journal of Dermatology|February 20, 2024
Prediction, screening and characterization of novel bioactive tetrapeptide matrikines for skin rejuvenationNathan Jariwala, Matiss Ozols, Alexander Eckersley, et al.Scientific Reports|January 15, 2020
The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty AcidsSarah Ducastel, Véronique Touche, Mohamed-Sami Trabelsi, et al.Journal of Enzyme Inhibition and Medicinal Chemistry|May 21, 2026
<i>In vitro</i> screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives <i>CDKN1</i> and <i>BBC3</i> expression to restore a p53-dependent cytotoxicitySimon Nannini, Céline Sieffert, Andrew McGown, et al.Alimentary Pharmacology & Therapeutics|September 10, 2014
Olmesartan-associated enteropathy: results of a national surveyL Marthey, G Cadiot, P Seksik, et al.Pageof 9